Dr. Lal PathLabs Limited

Equities

LALPATHLAB

INE600L01024

Healthcare Facilities & Services

Market Closed - NSE India S.E. 07:43:55 2024-07-19 am EDT 5-day change 1st Jan Change
2,994 INR +0.16% Intraday chart for Dr. Lal PathLabs Limited +1.46% +16.14%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Dr. Lal PathLabs Limited Declares Final Dividend for the Financial Year Ended March 31, 2024 CI
Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR2,713 From INR2,505 MT
Dr. Lal Pathlabs' Fiscal Q4 Consolidated Net Profit Rises; Share Up 6% MT
Transcript : Dr. Lal PathLabs Limited, Q4 2024 Earnings Call, May 10, 2024
India's Dr. LalPath Labs posts higher Q4 profit rises on healthy testing demand RE
Dr. Lal PathLabs Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024 CI
Dr. Lal PathLabs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024 CI
Dr Lal Pathlabs Names CEO MT
Dr. Lal PathLabs Limited Appoints Shankha Banerjee as Chief Executive Officer, Effective May 21, 2024 CI
Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer CI
Nomura Adjusts Dr. Lal Pathlabs’ Price Target to INR2,505 From INR2,465, Keeps at Neutral MT
Dr. Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q3; EPS, Revenue Miss Estimates MT
Dr. Lal PathLabs Seeks M&A CI
Transcript : Dr. Lal PathLabs Limited, Q3 2024 Earnings Call, Feb 01, 2024
India's Dr. Lal PathLabs posts 54% jump in Q3 profit on flu, COVID tests RE
Dr. Lal PathLabs Limited Approves Second Interim Dividend for the Fiscal Year 2023-24 CI
Dr. Lal PathLabs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Dr. Lal Pathlabs Board to Consider Second Interim Dividend for Fiscal 2024 MT
Nomura Upgrades Dr. Lal Pathlabs to Neutral From Reduce, Adjusts Price Target to INR2,465 From INR,2002 MT
Dr Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q2; Shares Climb 5% MT
Transcript : Dr. Lal PathLabs Limited, H1 2024 Earnings Call, Nov 02, 2023
Dr. Lal PathLabs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Dr. Lal Pathlabs Limited Approves to Declare Final Dividend for the Financial Year Ended March 31, 2023 CI
Dr. Lal PathLabs Limited Announces Change in Directorate CI
Chart Dr. Lal PathLabs Limited
More charts
Dr. Lal PathLabs Limited is an India-based provider of diagnostic and related healthcare tests and services in India. The Company offers patients and healthcare providers a range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Its tests include Pregnancy Test, Full Body Checkups, Covid 19 Test, Heart Test, Kidney Test, Liver Test, CBC Test, Cholesterol Test, Hepatitis B Test, Kidney Function Test, Liver Function Test, Sugar Test, Thyroid Test, Typhoid Test, Uric Acid Test, Vitamin B12 Test and Vitamin D Test. The Company has approximately 280 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore and Mumbai), 5,762 patient service centers (PSCs) and 11,619 pick-up points (PUPs). Its customers include individual patients, hospitals and other healthcare providers and corporate customers.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
2,994 INR
Average target price
2,588 INR
Spread / Average Target
-13.57%
Consensus
  1. Stock Market
  2. Equities
  3. LALPATHLAB Stock
  4. News Dr. Lal PathLabs Limited
  5. Dr Lal Pathlabs' Consolidated Profit Jumps in Fiscal Q1; Revenue Meets Estimates